Mycobacterium abscessus Complex Identification with Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry by Panagea, Theofano et al.
Mycobacterium abscessus Complex Identification with Matrix-Assisted
Laser Desorption Ionization–Time of Flight Mass Spectrometry
Theofano Panagea,a,b David H. Pincus,c Dorothy Grogono,d,e* Melissa Jones,f Josephine Bryant,g Julian Parkhill,g
R. Andres Floto,d,h Peter Gilliganb,f
Sismanogleio-A. Flemig General Hospital, Athens, Greecea; University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USAb; bioMérieux, Inc., Hazelwood,
Missouri, USAc; Cambridge Centre for Lung Infection, Papworth Hospital, Cambridge, United Kingdomd; University of Cambridge, Cambridge, United Kingdome; UNC
Health Care, Chapel Hill, North Carolina, USAf; Wellcome Trust Sanger Institute, Hinxton, United Kingdomg; Cambridge Institute for Medical Research, University of
Cambridge, Cambridge, United Kingdomh
We determined that the Vitek MS Plus matrix-assisted laser desorption ionization–time of flight mass spectrometry using re-
search-use-only (RUO) v.4.12 and in vitro-diagnostic (IVD) v.3.0 databases accurately identified 41 Mycobacterium abscessus
subsp. abscessus and 13 M. abscessus subsp. massiliense isolates identified by whole-genome sequencing to the species but not the
subspecies level, from Middlebrook 7H11 and Burkholderia cepacia selective agars. Peak analysis revealed three peaks poten-
tially able to differentiate between subspecies.
Nontuberculous mycobacteria (NTM) are emerging patho-gens with increasing prevalence in clinical settings in the in-
dustrialized world (1). Mycobacterium abscessus is emerging as a
significant respiratory pathogen accounting for a large proportion
of NTM disease in cystic fibrosis (CF) patients (2–6). They also
cause a variety of infections in non-CF patients, such as chronic
pulmonary, skin and soft tissue, and postsurgical infections (7).
Recent evidence (8, 9) supported by whole-genome sequenc-
ing (WGS) data (2) suggest that the M. abscessus complex com-
prises three subspecies M. abscessus subsp. abscessus (sensu stricto),
M. abscessus subsp. massiliense, and M. abscessus subsp. bolletii
although the taxonomy of this complex of organisms is debated.
Discrimination between them is clinically important due to the
differences in resistance and treatment response rates (1, 7, 10–14)
and relies on the sequencing of multiple genes such as erm(41),
23S rRNA, hsp65, and rpoB (11, 12, 15), which delays the result
and is expensive and time-consuming to perform in a routine
clinical microbiology laboratory.
Matrix-assisted laser desorption ionization–time of flight mass
spectrometry (MALDI-TOF MS) has been evaluated in several
studies, using different systems and different extraction protocols,
as an inexpensive, rapid, and efficient method in the identification
of mycobacteria (16–19).
In the present study, using a previously evaluated extraction
protocol (20), we determined the performance of two MALDI-
TOF MS databases for the identification of M. abscessus isolates
using a culture collection of M. abscessus isolates uniquely charac-
terized by WGS (2). Two solid media used in our laboratory to
isolate M. abscessus from clinical specimens, Middlebrook 7H11
and Burkholderia cepacia selective agar (BCSA), were evaluated.
We have previously shown that M. abscessus can be recovered on
BCSA from routine bacterial respiratory cultures of CF patients
(21). We also assessed the influence of culture age on the MALDI-
TOF identifications and the ability of the system to identify iso-
lates at the subspecies level and to detect genetic relatedness
among them.
Fifty-four mycobacterial clinical strains, 41 M. abscessus subsp.
abscessus and 13 M. abscessus subsp. massiliense isolated between
May 2005 and March 2013 in the Clinical Microbiology/Immu-
nology Laboratories at University of North Carolina Health Care
were initially identified as M. abscessus by sequential 16S rRNA
and hsp65 gene sequencing (22, 23). Isolates were identified to the
subspecies level by WGS, which was followed by phylogenetic
analysis (data not shown), each performed at the Wellcome Trust
Sanger Institute (Hinxton, United Kingdom) as described else-
where (2). Mycobacterial isolates were recovered from respiratory
samples of CF patients (n  43) and a variety of samples were from
non-CF patients, sputum (n  4), bronchial aspirate (n  1),
wound (n  3), abscess (n  1), biopsy specimen (n  1), and
blood (n  1).
Isolates were subcultured on Middlebrook 7H11 (BD Diagnos-
tic Systems, Sparks, MD) and BCSA plates (Remel Microbiology
Products; Thermo Scientific, Lenexa, KS) and incubated for an
equal amount of time, 3 to 4 days depending on growth rate, at
35°C with 5% CO2. The bioMérieux extraction protocol reported
on by Mather and colleagues was followed (20). The extracted
isolates were tested using the Vitek MS Plus system (bioMérieux
SA, Marcy l’Etoile, France) according to manufacturer’s recom-
mendations (20). Each extracted isolate was tested twice to avoid
acquisition errors. Escherichia coli ATCC 8739 was included in
each run as a positive control. Generated spectra were automati-
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cally compared to the research-use-only (RUO) Saramis Knowl-
edge Base (bioMérieux SA) database v.4.12 with the use of Saramis
Premium software as well as the draft (development) in vitro-
diagnostic (IVD) v.3.0 database with the use of an R&D software
(SpectraIdentifier R2.1.0), and the identification confidence
scores (IDCSs) were recorded. IDCS is the identification confi-
dence level for the best match to the database. Unidentified iso-
lates were considered strains on double testing and individual
spectra that gave an IDCS of 75% against the RUO Saramis
Knowledge Base and more than four matches against the IVD
v.3.0 database. For those isolates where no matches were found,
extraction and testing were repeated.
All 54 isolates were accurately identified as M. abscessus by the
Vitek MS Plus system with each database and each medium, ex-
cept one isolate on Middlebrook 7H11 and one on BCSA against
RUO Saramis Knowledge Base, for which M. abscessus was never-
theless the closest match. Extraction was repeated for one isolate
that yielded no match with either database. Average IDCSs were
91.4% and 93.7% (P  0.062) for Middlebrook 7H11 and BCSA,
respectively, against the RUO v.4.12 database and 99.9% against
the IVD v.3.0 database for each medium. Out of 23 individual
spectra that yielded no identification with the RUO v.4.12 data-
base, only two remained unidentified when the IVD v.3.0 database
was used for comparison.
Databases available at the time of this study did not discrimi-
nate at the subspecies level. Our results are consistent with previ-
ous reports using either the Biotyper (Bruker Daltonics) (17–20)
or Vitek MS system (bioMérieux SA) (20, 24) despite the differ-
ences in the isolation media, extraction protocol, and databases
used.
In order to assess the effect of culture age on the system’s per-
formance, 10 phylogenetically distinct isolates, 7 M. abscessus
subsp. abscessus and 3 M. abscessus subsp. massiliense, were tested
from Middlebrook 7H11 and BCSA after 72 h, 96 h, and 120 h of
incubation. Each strain was subcultured on the above media on
three consecutive days to simultaneously yield cultures at all three
growth stages and include them in the same run in order to avoid
inter-run variation.
Although strains were successfully identified as M. abscessus at
all time points, the average mean IDCS with the RUO v.4.12 da-
tabase decreased significantly at 120 h compared to 72 h and 96 h
for each medium (repeated measure analysis, P  0.05). In detail,
the score decreased from 96.6% and 91.3% at 72 h and 94% and
91.4% at 96 h to 83.5% and 86.5% at 120 h for 7H11 and BCSA,
respectively (Fig. 1). Our data are in accordance to the results of
Mather et al. (20) who also observed a decline on identification
confidence scores with the progression of culture age, possibly
attributed to differences in the colony age used for database cre-
ation, which one can overcome by lowering the threshold used for
identification. No decline in IDCS was observed for either me-
dium when the IVD v.3.0 database was used; all IDCS were 99.9%
at all time points due to the different algorithm used for the con-
struction of the IVD v.3.0 database. Nevertheless, it is preferable to
test colonies at a younger stage of growth, as soon as one is able to
distinguish between different morphotypes, in order to achieve
the closest match to the existing databases.
Finally, a dendrogram was created with the isolates’ spectra
generated from Middlebrook 7H11 using Saramis Premium soft-
ware. Neither strain belonging to the same subspecies nor genet-
ically related ones clustered separately (data not shown), suggest-
ing an inability to use the Saramis algorithm for automated
identification of these two subspecies or for detection of their
FIG 1 Effect of culture age on MALDI-TOF MS performance using the RUO v.4.12 and IVD v.3.0 databases. The average mean IDCS decreased significantly at
120 h compared to 72 h and 96 h for each medium. When the IVD v.3.0 database was used, no decrease was observed at all time points or in either medium.
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clonality. Nevertheless, subsequent peak analysis (performed
manually using 0.08% tolerance to define peak equivalence, also
used by the Saramis software) revealed three peaks differentially
present among the two subspecies, averaged at 8,508.66 m/z,
9,473.31 m/z, and 8,769.01 m/z. In detail, peak 8,508.66 m/z was
present in 11/13 (84.6%) M. abscessus subsp. massiliense and ab-
sent from 39/41 (95.1%) M. abscessus subsp. abscessus isolates,
peak 9,473.31 m/z was absent from all 13 M. abscessus subsp.
massiliense and present in only 7/41 (17%) M. abscessus subsp.
abscessus isolates, and peak 8,769.01 m/z was absent from all 41
M. abscessus subsp. abscessus and present only in 5/13 (38.4%) M.
abscessus subsp. massiliense isolates (Table 1). We speculate that
the last two peaks are identical with the ones generated by the
Bruker Biotyper at 9,477.48 m/z and 8,771.73 m/z published by
Teng et al. (25) and reported to be 100% specific for M. abscessus
subsp. abscessus and M. abscessus subsp. massiliense, respectively.
Additionally, peaks published by Fangous et al. (26) were also
evaluated, and the only peaks observed were the ones at 2,081 m/z
and 3,378 m/z. The 2,081 m/z peak was found to be less sensitive
and specific than reported, as it was not uniformly present in M.
abscessus subsp. abscessus (13/41) while also present in 1/13 M.
abscessus subsp. massiliense, whereas the 3,378 m/z peak was—
similarly to the Fangous et al. (26) publication—present in all
isolates of the two subspecies. Unfortunately, we are unable to
evaluate its use on M. abscessus subsp. bolletii identification since
such isolates were not found in our patient population and ana-
lyzed by WGS.
Identification of the different subspecies is important in the
clinical environment. Clarithromycin, used for the treatment of
these infections (6, 10), is more effective against M. abscessus
subsp. massiliense lung infections, while resistance is common in
M. abscessus subsp. abscessus and M. abscessus subsp. bolletii iso-
lates (11–13, 27). Additionally, there is differential susceptibility
to various antimycobacterial drugs (1, 14). Our data, although
insufficient due to the lack of M. abscessus subsp. bolletii isolates,
enhance the already existing literature, which suggests the poten-
tial of MALDI-TOF MS to identify subspecies within the M. ab-
scessus complex.
In conclusion, MALDI-TOF MS is a powerful technique capa-
ble of accurate and rapid identification of M. abscessus isolates not
only from specific mycobacterial culture media but also from se-
lective media used to detect B. cepacia complex isolates in routine
bacterial cultures of CF patients. The IVD v.3.0 database provides
excellent results on M. abscessus identification, minimizing un-
identified results compared to RUO Saramis Knowledge Base
v.4.12. A current potential shortcoming of each bioMérieux data-
base for M. abscessus evaluated in this study is that they were gen-
erated using isolates (18 for RUO Saramis Knowledge Base v4.12
and 20 for IVD v3.0) of M. abscessus identified only to the species
level. The inability to automate identification to the subspecies
level then was expected. However, MALDI-TOF technology is
sometimes inadequate to differentiate at the subspecies level even
when reference identification to subspecies is included in the da-
tabase. As molecular tools are applied to further unravel the tax-
onomy of a variety of emerging human bacterial and fungal
pathogens, an evolution of MALDI-TOF databases will be re-
quired. Studies such as this one using WGS as the reference
method demonstrate the current shortcomings but also the prom-
ise of this technology.
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